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Prevention Of Opportunistic Infections (OIs)
In Those With HIV Infection
Joseph Bick, M.D.*, Director, HIV Treatment Services, California Medical Facility, Vacaville, CA, California DOC

Prior to the availability of effective antiretroviral
therapy (ART), most patients with HIV infection
could expect to experience a fairly predictable
and inexorable decline in their CD4 count. Once
a patient’s CD4 count declines significantly, prophylaxis for opportunistic infections is initiated
and continues indefinitely.

many common OIs. These recommendations
are also not significantly changed from prior
USPHS/IDSA recommendations and are summarized in Table 2 on page 4.

Beginning in 1995, the availability of more effective protease inhibitor based ART forever altered
this algorithm. With more potent ART, many
patients experience significant and sustained
improvements in immunologic function as evidenced by CD4 count increases and in vitro
responses to antigenic stimulation. Soon the
question arose whether those who during CD4
nadir met criteria for prophylaxis still required
such agents after experiencing ART-induced
immune reconstitution.

For many of the most common OIs, data exists
to support the discontinuation of secondary prophylaxis in those with sustained ART-induced
immunologic recovery. Such an approach carries the potential for decreasing the potential for
side effects, drug-drug interactions, total pill burden, and the significant costs associated with
some prophylactic medications. (Per annum
costs: clarithromycin 500 mg bid $2,843; fluconazole 200 mg qd $4,603; ganciclovir 1000
mg tid $17,794.) Table 3 details updated recommendations for starting, discontinuing, and
restarting primary and secondary prophylaxis for
some of the most devastating HIV associated
opportunistic infections. For many OIs, the evidence for efficacy of continued prophylaxis
might not outweigh the potential adverse consequences.

Initial anecdotal reports gave way to longer
observational trials. When last reviewed in
HEPP News,1 some data existed that supported
stopping primary and secondary prophylaxis in
the setting of sustained ART-induced CD4 count
increases. Subsequently, further information has
accumulated that has now lead to a revision in
the United States Public Health Services/
Infectious Diseases Society of America
(USPHS/IDSA) Guidelines for the Prevention of
Opportunistic Infections in HIV Infected Adults
and Adolescents. The revised version of these
recommendations, released November 28,
2001, is available at www.HIVATIS.org/trtgdlns.html. Some important aspects of these
guidelines will be summarized here.

Initiating Primary
Prophylaxis to Prevent OIs
The recommendations for prevention of disease
related to Pneumocystis carinii, Mycobacterium
tuberculosis, Mycobacterium avium complex,
Toxoplasma gondi, Streptococcus pneumonia,
Hepatitis A and B, influenza, and Varicella are
available and have not significantly changed
from the prior guidelines. Some are summarized
in Table 1 on page 2.

Initiating Secondary
Prophylaxis To Prevent OIs
After treatment of active disease, secondary prophylaxis is recommended to prevent relapse of

Providence, RI 02906

401.277.3651

Criteria For Discontinuing
Primary And Secondary
Prophylaxis

Each patient must be approached on an individualized basis. Discontinuing prophylaxis carries
some risk for those patients who will not have
access to frequent medical evaluation and blood
test monitoring. In some such cases it may be
most prudent to continue prophylaxis until such
time as the patient can be monitored more closely.
For patients who can be followed closely, data
support discontinuing primary prophylaxis in
those whose CD4 count in response to ART has
for at least 3 months remained >100
(Mycobacterium avium complex) or >200
(Pneumocystis, Toxoplasmosis).
Continued on page 2
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Opportunistic Infections...
(continued from page 1)

For patients who have experienced active
disease due to Pneumocystis, Toxoplasma,
Mycobacterium Avium, Cryptococcus, and
Cytomegalovirus, criteria are provided for
the discontinuing of secondary prophylaxis
(see Table 3). Again, this should be undertaken on an individualized basis and only
after the patient is educated about the risks
and benefits involved with each approach.
For some patients, the ability to be rewarded for good ART adherence by stopping
prophylactic medications may serve as an
additional incentive to continue to comply
with ART.

Risk Avoidance: Sexual
and Injection Drug
Exposures
Recommendations intended to help HIV
infected individuals avoid exposure to or
infection with opportunistic infections is
provided and categorized by risk group.
Clearly, at least some prisoners will continue to be sexually active while incarcerated
and some will engage in injection drug use
(IDU). In spite of the fact that both activities
are prohibited in correctional facilities,
patients need more educational information
than “just say no.” Sexual and IDU abstinence is the safest option for those interested in reducing the risk for acquisition of
CMV, HSV, HPV, HHV8, other HIV strains,
HAV, HBV, HCV and a variety of other
enteric pathogens. Acknowledging that risk
behaviors continue during incarceration,
prisoners should be provided harm reduction educational information detailing how
to decrease health risks if they choose to
continue to be sexually active and/or
engage in IDU. Patients should be instructed about which sexual practices carry the
greatest health risks to them and their partners. To decrease the risk for enteric infections such as cryptosporidium, salmonella,
shigella, campylobacter, amebiasis, giardiasis, and hepatitis A, patients should
avoid sexual practices that might result in
oral exposure to feces. All non-immune
prisoners should be offered vaccination for
hepatitis B. Non-immune IDUs and men
who have sex with men should be offered
vaccination for hepatitis A. In those systems in which they are available, prisoners
should use latex condoms during every act
of sexual intercourse. [As this issue of
HEPP News went to press, the Los
Angeles county jail joined a handful of correctional facilities in this country that make
condoms available to prisoners].
Prisoners with a history of IDU should be
provided substance abuse treatment, and
linked to community services at the time of
parole. Recognizing the reality that many
individuals will relapse to IDU during or following incarceration, patients should be
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Table 1: Opportunistic Infection Prophylaxis to Prevent First Infection
(Strongly recommended standard of care)2

Pathogen

Indication

First Choice
Preventive
Regimen

Alternative Preventive Regimen

Pneumocystis
carinii

CD4+ count
<200/µ L or
oropharyngeal
candadiasis

Trimethoprimsulfamethoxazole (TMP-SMZ)
1 DS or SS po
qd (AI)

Dapsone 50 mg po bid or 100mg po
qd (BI); dapsone 50 mg po qd plus
pyrimethamine 50 mg po qw plus
leucovorin 25 mg po qw (BI); dapsone 200 mg po plus pyrimethamine
75 mg po plus leucovorin 25 mg po
qw (BI); aerosolized pentamidine 300
mg q month via Respirgard II nebulizer (BI); atovaquone 1500 mg po qd
(BI); TMP-SMZ 1 DS po tiw (BI)

Toxoplasma
gondii

IgG antibody
TMP-SMZ 1 DS
to Toxoplasma po qd (AII)
and CD4+
count <100/µ L

TMP-SMZ 1 SS po qd (BIII); dapsone 50 mg po qd plus
pyrimethamine 50 mg po qd plus leucovorin 25 mg po qw (BI); atovaquone 1500 mg po qd with or without pyrimethamine 25 mg po qd plus
leucovorin 10 mg po qd (CIII)

Mycobacterium
avium
complex

CD4+
count<50/µ L

Significant
Varicella
exposure to
Zoster
Virus (VZV) chicken pox or
shingles for
patients who
have no history of either
condition, or, if
available, negative antibody
to VZV

Azithromycin‡
1200 mg po qw
(AI), or clarithromycin 500
mg po bid (AI)
Varicella zoster
immune globulin
(VZIG) 5 vials
(1.25 mL each)
im, administered
<96 h after
exposure, ideally
within 48 h (AIII)

Rifabutin 300 mg po qd
(CI);azithromycin 1200 mg po qw
plus rifabutin 300 mg po qd.

Ratings:
A. Should always be offered
B. Should generally be offered
C. Optional
D. Should generally NOT be
offered
E. Should NEVER be offered

Quality of Evidence:
I. Evidence from at least one properly randomized, controlled trial
II. Evidence from at least one well-designed clinical trial without randomization, from
cohort or case-controlled analytic studies (preferably from more than once center), or
from multiple time-series studies. Or dramatic results from uncontrolled experiements.
III. Evidence from opinions of repsected authorities based on clinical experience, descriptive studies, or reports of expert committees.
educated to never share or re-use
syringes, needles, or drug preparation
equipment. Those who will be re-using
injection equipment should be advised to
clean all materials with bleach and water.
Furthermore, inmates should be educated
on syringe availability and encouraged to
use services such as pharmacy purchase
and needle exchange where available, and
to explore the possibility of physician prescription when other services are not available.3 Non-immune IDUs should be vaccinated for hepatitis A and B.

Risk Avoidance:
Occupational Exposures
HIV infected prisoners do hold jobs while
incarcerated that can place them at risk for
significant OIs. Those working in sanitation,
janitorial or laundry positions can come into
contact with body wastes, contaminated
sharps, and other materials that can transmit diseases. All such workers should be

provided personal protective equipment
and educated in its use. All non-immune
workers should be offered vaccination
against hepatitis A and B. As a rule, prisoners should not be involved in direct patient
care. In those systems that allow such
work, inmate workers should be provided
hepatitis B vaccination.
In areas endemic for histoplasmosis, HIV
infected prisoners should avoid activities
that are associated with an increased risk
for infection with this organism. Examples
include cleaning or remodeling old buildings, disturbing the soil beneath bird roosting sites, and cleaning chicken coops.
Similarly, in areas endemic for coccidioidomycosis, patients should avoid extensive exposure to disturbed native soil as
might occur during agricultural work or
building excavation.
Continued on page 4
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Letter from the Editor
Dear HEPP News Readers,
This month, HEPP is addressing opportunistic infections and fevers of unknown origins. As
the treatment of HIV has improved over the years, what we consider opportunistic infections
has shifted considerably. Dr. Bick has done his usual excellent job in presenting our current
and past thoughts on OIs. Although previous issues have discussed it, hepatitis is rapidly
becoming our most lethal co-infection. More and more authors are including hepatitis as an
opportunistic infection. Likewise, more and more correctional systems are having to face the
reality of hepatitis C in their populations. All of us will be significantly relieved when we have
better treatment regimens for this disease complex, especially the genotype 1 series that is
so prevalent in our environment.
We all hope that with better and better control of HIV disease, with mechanisms to make
sure our patients get every dose every time, with newer and easier regimens, and with more
potent anti-virals, that opportunistic infections that plagued us just five years ago and
destroyed our patients’ lives and quality of life, will be a distant medical memory. In some
significant sized systems, there has not been a case of CMV retinitis in over two years.
Although it will be unlikely because of late diagnoses in some of our patients, hopefully PCP
pneumonia and Mycobacterium avium complex will become important only in the history of
medicine textbooks.
Fevers of unknown origin (FUO) is a very complex subject that is addressed very succinctly in this issue. The challenges presented by a patient with an FUO are enough to make the
hardiest diagnostician quake, especially when other signs and symptoms, laboratory analyses, and radiography are not helpful.
After reading this issue, health care providers should understand the steps involved in working-up a fever of unknown origin and the various treatment regimens recommended for
opportunistic infections.
Please enjoy this issue. Not only is it another intellectually stimulating and challenging presentation, but this journal touches us all right where we live. It is so relevant to our daily
lives. The authors and editors have done a great job in making this journal the top of the line
in its field.
Sincerely,
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Opportunistic Infections...
(continued from page 2)

Risk Avoidance: Food
Related Exposures
Prisoners commonly store food in their cells,
and rarely have access to refrigeration or a
way to reheat leftovers. Patients should be
warned about the risks associated with eating food that has been improperly stored or
cooked. Prisoners may receive food during
visits or in packages from home. Soft
cheeses such as Mexican style queso fresco
carry a risk for listeriosis and should be
avoided by those who are HIV infected.
Correctional staff should routinely monitor
the facility’s kitchen practices to ensure that
all meat and poultry are appropriately
cooked (to an internal temperature of 180°
for poultry, and 165° for meat.) All produce
should be washed, and procedures should
be in place to ensure that uncooked meat
and poultry does not come into contact with
other foods. All counters, cutting boards,
knives, and utensils should be thoroughly
cleaned after being used to prepare
uncooked meat, poultry, and fish. Although
there is no medical justification for the exclusion of those with HIV, hepatitis B, or hepatitis C from working in food service, those with
diarrhea, open lesions on their hands or
arms, or acute hepatitis A should not work as
food handlers. Providers may consult the
NCCHC guidelines, including “P-16: Kitchen
Sanitation and Food Handlers” for further
recommendations.
In conclusion, HIV-infected prisoners are at
significant risk for a wide variety of OIs.
Information exists which can assist our
patients to avoid exposure to and infection
with many of these organisms. Through
patient education and the appropriate use of
immunizations, morbidity and mortality due
to OIs can be avoided. Data are also accumulating to support the discontinuation of OI
prophylaxis in those who have experienced
ART-induced immunologic recovery. The
USPHS/IDSA guidelines provide guidance to
clinicians and patients who are considering
withdrawing preventive therapy for the most
common OIs.
*Nothing to disclose.
‡
During pregnancy, azithromycin is recommended
instead of clarithromycin due to the teratogenicity
of clarithromycin in animals.
References:
1. “Prevention of Opportunistic Infections.”
HIV101, HEPP News. 2000 October.
2. 2001 USPHS/IDSA Guidelines for the
Prevention of Opportunistic Infections in Persons
Infected with Human Immunodeficiency Virus. On
the web at http://www.hivatis.org/guidelines/other/
OIs/OIGNov27.pdf
3. Burris et al. Ann Intern Med. 2000;133:218-226.
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Table 2: Prophylaxis to Prevent Recurrence of Opportunistic Disease
in Adults (Secondary Prophylaxis)
First Choice Preventive
Regimen

Pathogen

Alternative Preventive
Regimens

Pneumocystis same as primary prophylaxis; see Table 1
carinii
Toxoplasmosis gondii

same as primary prophylaxis; see Table 1

Mycobacterium avium
complex

Clarithromycin‡ 500 mg po bid (AI) Azithromycin 500 mg po qd (AII)
plus ethambutol 15 mg/kg po qd;
plus ethambutol 15 mg/kg po qd
(AII); ± rifabutin 300 mg po qd (CI) ± 300 mg po qd (CI)

Cytomegalovirus

Ganciclovir 5-6 mg/kg/day iv 5-7
days/wk or 1000 mg po tid (AI);
foscarnet 90-120 mg/kg iv qd (AI);
(for retinitis) ganciclovir sustainedrelease implant q 6-9 mo plus
ganciclovir 1.0-1.5 g po tod (AI)

Cidofovir 5 mg/kg iv qow +
probenecid 2 g po 3 h before the
dose followed by 1 g po 2 h after
the dose and 1 g po 8 h after the
dose (total of 4 g) (AI); fomivirsen
1 vial (330 mg) injected into the
vitreous then repeated every 2-4
wks (AI); valganciclovir 900 mg
po qd (BI)

Table 3: Guidelines for Discontinuing and Restarting Primary and
Secondary Prophylaxis for Opportunistic Infections2
Opportunistic
Infection

Indications
Indications
for
for
Restarting
0
Discontinuing
1
Prophylaxis
10 Prophylaxis

Indications
for Discontinuing 20
Prophylaxis^

Indications
for
Restarting
20 Prophylaxis

Pneumocystis
carinii
Pneumonia
Toxoplasma

CD4+ >200
cells/µL for >3
months (AI)

CD4+ <200
cells/µL (AIII)

CD4+ >200
cells/µL for >3
months (BII)

CD4+ <200
cells/µL (AIII)

CD4+ >200
cells/µL for >3
months (AI)

CD4+ <100-200
cells/µL (AIII)

CD4+ <200
cells/µL (AIII)

Mycobacterium
avium
complex

CD4+ >100
cells/µL for >3
months (AI)

CD4+ <50-100
cells/µL (AIII)

Cytomegalo
virus
retinitis

Not applicable

Not applicable

Cryptococcosis

Not Applicable

Not Applicable

CD4+ >200
cells/µL sustained (>6 mo)
and completed
initial therapy
and asymptomatic for toxo
(CIII)
CD4+ >100
cells/µL sustained (>6 mo)
and completed
12 mo of MAC
therapy and
asymptomatic
for MAC (CIII)
CD4+ >100-150
cells/µL sustained (>6 mo)
and no evidence
of active disease
and regular
opthalmic examination (BII)
CD4+ > 100-200
cells/µL sustained (6 mo)
and completed
initial therapy
and asympotamtic for
cryptococcosis
(CIII)

^ After active disease.

CD4+ <100
cells/µL (AIII)

CD4+ < 100-150
cells/µL (AIII)

CD4+ < 100-200
cells/µL (AIII)
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Management of Fever of Unknown Origin
IV line or neutropenia (<500/mm2)

NO

Consult appropriate algorithm:
W Headache, neurological
symptoms: neurologic algorithm
W Cough, dypsnea: pulmonary
algorithm
W Diarrhea: diarrhea algorithm
Other focal findings:
W Nasal symptoms: evaluate
for sinusitis
W IV line: blood cultures +
antibiotics ± line removal with
roll culture
W Soft tissue inflammation:
aspirate/biopsy for culture, CT
scan
W Adenopathy: lymph node
biopsy/aspirate
W Abdominal pain: LFTs, amylase, CT scan

YES

Review medications and
confirm fever

Blood cultures,
CBC, Liver Function Tests
(LFTs), Chest X-ray

Patient Receiving Drugs
Likely to Cause Fever:

While waiting for results, treat with
empiric antibiotics + G-CSF

Common: Sulfonamides,
Dapsone, Amphotericin
B, Phenytoin, Penicillins,
Barbiturates, Bieomycin,
Carbemazepine,
Thalidomide,
Pentamidine,
Clindamycin
Less Common:
Salicylates,
Cephalosporins, INH.
Rifampin, Streptomycin,
PAS, Cocaine products,
Azathioprine

NO

No drug cause: Initial
Evaluation
*Screening Tests:
W CBC, differential, CD4 count
W Chemistry panel, LDH
W Urine culture and analysis
W Blood culture
W PPD and anergy screen
W CD4 count <300/mm3;
mycobacterial blood culture and
serum cryptococcal antigen
Chest x-ray±blood
gasses/oximetry

M. avium bacterium
(most common cause
FUO) Treat

Responds and/or blood
culture positive

No response and
cultures negatives

Treat

Screening tests *

Positive

Negative

YES

Drug holiday

No
response

Responds to
discontinuation of agent

LFTs abnormal:
Cholestasis changes:
ultrasound or CTERCP
or biopsy Granulomas:
M. avium, TB, histoplasmosis
Cholangiopathy: CMV,
cryptosporidia,
microsporidia, lymphoma, KS, idiopathic
(30%)
Hepatocellular: hepatitis
viruses
ETOH, drug-induced,
CMV, HSV

Crypt Ag positivelumbar
puncture and
treat

Cytopenia
bone marrow
aspirate/biopsy

Abnormal
chest x-ray or
hypoxemia
pulmonary
algorithm

Next Round of Tests:
W Evaluate for TB: culture sputum, urine
W CT scan abdomen,
chest±head
W Histoplasmosis:
Antigen assay blood and
urine
W Lumbar puncture: CSF
analysis
W Evaluate sinusitis and
dental source
W Lymphoma: Node
biopsy, LDH, liver/marrow biopsy
W Biopsy liver (rarely pos
with normal LFTs)
W Gallium scan, indium
WBC scan; rarely useful
W Biopsy marrow: yield
lower than liver biopsy

*Screening Tests:
W CBC, differential, CD4 count
W Chemistry panel, LDH
W Urine culture and analysis
W Blood culture
W PPD and anergy screen
W CD4 count <300/mm3; mycobacterial
blood culture and serum cryptococcal antigen Chest x-ray±blood gasses/oximetry

Adapted from Bartlett JG, Gallant JE. 2001-2001 Medical Management
of HIV Infection. Johns Hopkins University, Baltimore, MD 2001 (356).
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NCCHC Shines in New Mexico

By Joseph Paris, M.D.*, Medical Director, GA Department of Corrections, Rebecca Nerenberg**, Managing Editor, HEPP News
The 25th National Conference on Correctional Health Care ended
last month in Albuquerque, NM. The weather cooperated nicely and
a string of beautiful days in very pleasant surroundings enhanced
this premier correctional health care meeting, which lasted from
November 10 through 14, 2001. Total attendance was close to the
2,000 mark.
Prior to the conference proper, there were a number of seminars
including an in-depth look at the NCCHC Standards, a meeting of the
Society of Correctional Physicians, and a well-attended HEPP symposium entitled “Bridging the Gap: Getting High Risk Patients into
Treatment.” The HEPP meeting covered current topics in infectious
disease in corrections including the outbreak of hepatitis B in the
Georgia Department of Corrections. Dr. Joseph Paris from the
Georgia Department of Corrections related the episode, presenting
Dr. Amy Kahn's, Centers for Disease Control, findings.
Dr. Paris stated that following the discovery of an acutely jaundiced
male in a Georgia prison, the CDC interviewed and tested potential
contacts at the same dormitory and was able to initially uncover an
additional group of 5 more inmates acutely infected with hepatitis B
but completely asymptomatic. Additional interviews and testing of the
remainder of the prison population revealed the presence of another
group of 5 acutely infected, asymptomatic hepatitis B patients. None
of the 11 developed serious complications of hepatitis B. Risk factors
for intramural transmission of hepatitis B in the prison settings were
tattooing, homosexual sex, and body fluid exposures in general,
activities that are clearly not condoned by the Georgia DOC.
This was the first completely documented example of intramural
transmission of hepatitis B in prison settings. Furthermore, it seems
that for every overt, symptomatic acute hepatitis B case, one would
expect the presence of 10 more cases. However, testing and interviewing in a timely manner are necessary to discover these cases.
Vaccination of the susceptible inmates did take place at the Georgia
prison, but vaccination for the entire state prison population has not
yet occurred; however, a budget for that purpose was requested by
Dr. Paris and is being considered by the Appropriations Committee
of the Georgia legislature.
A companion presentation on the national picture on inmate risk of
hepatitis B was given by another of the CDC researchers involved in
the outbreak, Dr. Robert Lyerla. Additional presentations at the HEPP
symposium included a discussion of tuberculosis in corrections as
presented by Dr. Anne De Groot, which highlighted the TB situation

in prisons with “real life lessons” learned from TB outbreaks in New
York, South Carolina, and California. Dr. De Groot also gave a talk
on HIV-infected women, highlighting the differences in the way HIV
affects women and men including the new information on differences
in viral load between men and women when they progress to AIDS.
Dr. Joe Bick of the California Department of Corrections gave a presentation entitled “Getting Transgendered Patients into Treatment” in
which he explained the issues these patients face and described how
their gender identification affects their HIV treatment.
Dr. Eric Avery, a psychiatrist from the University of Texas Medical
Branch in Galveston, presented the various anti-depressant medications available along with their side effects. He also described how
mental health and HIV treatment information must be available in pictorial form for incarcerated patients, as many of them do not read.
Dr. Michael Wong also gave a comprehensive presentation on
Hepatitis C virus (HCV) in corrections at the HEPP symposium. Dr.
Wong presented HCV as a single infection as well as the interaction
of HCV and HIV in a coinfected individual.
During the Conference proper, there were Plenary Sessions and
Concurrent Sessions including HCV-related sessions delivered by
Newton Kendig, MD Arthur Brewer, MD, Berel Arrow, MD, Joseph
Paris MD, and Anne Spaulding MD; HIV-related sessions delivered
by Bill Ruby, DO, John Bartlett, MD, and David Thomas, MD; a session describing Research in Corrections by Thomas Conklin, MD;
sessions describing legal issues delivered by Roderic Gottula, MD,
William Rold, JD; a session on Oral Health presented by Thomas
Shields, DDS and John Battle, DMD; a session on Diabetes
Monitoring presented by Michael Puerini, MD; and a session on
Correctional Physician Productivity presented by Joseph Paris, MD.
Other concurrent sessions tackled important issues in Nursing,
Pharmacy, Mental Health, Education, Juvenile Offenders, Female
Prisoners, Medical School Involvement, among others. The
Conference provided a veritable cornucopia of timely topics and
attendees had to make agonizing choices between outstanding,
simultaneous sessions.
The next NCCHC Meeting will be held in October 19-23, 2002, in
Nashville, Tennessee.
*Nothing to disclose.
**Nothing to disclose.

Resources & Websites
Powerpoint presentations from the HEPP NCCHC preconference
symposium available in electronic form. Topics include: the correctional side of HCV, HBV, TB, HIV in women, Mental Health in HIV-positive
patients, and information on treating transgendered patients. Email
HEPPNews@brown.edu

Canadian HIV/AIDS Legal Network
Background and Information sheets available on testing of persons
believed to be the source of an occupational exposure to HBV, HCV,
or HIV. In English and French at
http://www.aidslaw.ca/Maincontent/issues/testing.htm

Opportunistic Infections

HIV/AIDS Annual Update 2001
A collection of 11 clinical reviews now available on Medscape.
http://hiv.medscape.com/update2001

USPHS/IDSA Opportunistic Infection Treatment Guidelines
http://www.hivatis.org/guidelines/other/OIs/OIGNov27.pdf
AEGIS Information on Opportunistic Infections
http://www.aegis.com/topics/oi/
AIDS Treatment Data Network Definitions of OIs
http://www.aidsinfonyc.org/network/oisgloss.html
CDC Fact Sheets on Drug Users in the US Criminal Justice
System
http://www.cdc.gov/idu/criminaljustice.htm

HIV Treatment
AMFAR HIV/AIDS Treatment Directory, Summer 2001 Edition
For free copies, contact Barbara Good at barbara.good@amfar.org or
fax a request to 212.806.1601
Updated Adult and Adolescent HIV Treatment guidelines
http://www.hivatis.org/guidelines/adult/Aug13_01/pdf/AAAug13S.PDF
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Treatment of Opportunistic Infections
The following are recommended as standard of care.1,2

Alternative Treatment

W Trimethoprim (TMP) 15 mg/kg/day + sulfamethoxazole
(SMX)75mg/kg/day PO or IV x 21 days in 3-4 divided
doses (typical oral dosage is 2 DS tid)

W TMP15mg/kg/day PO + dapsone 100mg/day PO x 21 days
W Pentamidine 4mg/kg/day IV x 21 days (often reserved for
severe cases)
W Clindamycin 600mg IV q8h or300-450mg PO q6h + primaquine 30 mg/day base PO x 21 days
W Atovaquone 750mg suspension PO with meal bid x 21 days
W Trimetrexate 45 mg/m2/day + folinic acid 20 mg/m2 or IV
q6h

W Pyrimethamine 100-200 mg loading dose; then 50-100
mg/day PO + folinic acid 10mg/day PO + sulfadiazine or
trisulfapyrimidime 4-8 g/day PO for at least 6 weeks

W Pyrimethamine + folinic acid (see preferred regimen) + clindamycin 900-1200* mg IV q6h or 300-450 mg PO q6h for at
least 6 weeks
W Pyrimethamine and folinic acid (see preferred regimen)
plus one of the following: azithromycin 1200-1500 mg/day,
clarithromycin 1 g bid, or atovaquone 750 mg qid with food
W Azithromycin + 900 mg PO x 2 first day, then 1200
mg/day x 6 weeks, then 600 mg/day (patients <50
kg receive half dose) (salvage therapy)

W Clarithromycin 500 mg PO bid plus Ethambutol (EMB)
15 mg/kg/day PO

W Azithromycin 600 mg/day PO in place of clarithrmycin +
Ethambutol (EMB) ± Rifabutin (RFB) (same doses)
W Combination treatment with amikacin 10-15 mg/kg/day IV
or ciprofloxacin 500-700 mg bid

Dermatomal:
W Acyclovir 800 mg PO 5x/day at least 7 days (until
lesions crust) or famciclovir 500 mg PO tid or valacyclovir
1 g PO tid x >7 days
Disseminated, opthalmic nerve involvement or visceral:
W Acyclovir 30-36 mg/kg/day IV at least 7 days
Acyclovir-resistant strains:
W Foscarnet 40 mg/kg IV q8h or 60 mg/kg q12h

Dermatomal:
W Acyclovir 30 mg/kg/day IV
W Foscarnet 40 mg/kg IV q8h or 60 mg/kg IV q12h
Disseminated, opthalmic nerve involvement or visceral:
W Foscarnet 40 mg/kg IV q8h or 60 mg/kg IV q12h
Acyclovir-resistant strains:
W Cidofovir IV
W Topical trifluridine

W Intraocular ganciclovir implant (Vitrasert) q6
months+oral valganciclovir 900 mg/day
W Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h x 14
to 21 days
W Ganciclovir 5 mg/kg IV bid x 14 to 21 days
W Valganciclovir 900 mg PO bid x 21 days, then 900
mg/day
W Cidofovir 5 mg/kg IV q week x2, then 5 mg/kg q 2
weeks + probenecid, 2 g PO 3 hours before each dose,
1 g PO at 2 and 8 hours post dose (total of 4 g)

W Alternating or combining foscarnet and ganciclovir
W Intraocular injections of foscarnet 1.2-2.4 mg in 0.1 mL (N
Engl J Med 1994;330:868) or ganciclovir 2000 µg in 0.05-0.1
mL (Br J Ophthal 1996;80:214).
W Fomivirsen, 330 mg by intravitreal injection day 1 and 15,
then monthly

Mild:
W Acyclovir 400 mg PO tid or famciclovir 250 mg PO tid
or valacyclovir 1.0 g PO bid; all given for 7 to 10 days
Severe or Refractory:
1. Acyclovir up to 800 mg PO 5x/day or
15-30 mg/kg/day IV at least 7 days
2. Valacyclovir 1 g PO bid-tid

Severe or Refractory:
W Foscarnet 40 mg/kg IV q8h or 60 mg/kg q12h x 3 weeks
W Topical trifluridine as 1% ophthalmic solution q8h
Alternative topical agents:
W Cidofovir 3% and foscarnet 1% cream
W Cidofovir 5 mg/kg q 2 weeks (limited experience)

Varicella Zoster

M. avium
complex
(MAC)

Toxoplasma gondii

Pneumocystis carinii

Preferred Treatment

Cytomegalovirus
Retinitis (CMV)*

By Rebecca Nerenberg^, Managing Editor, HEPP News

Herpes Simplex

HIV 101

December 2001

*Initital Treatment Recommendations of the IAS-USA (Arch Intern Med 1998;158:957). For information on maintenance and
other forms of therapy, consult reference below.
^Nothing to disclose.
References:
1. Bartlett JG and Gallant JE. 2001-2002 Medical Management of HIV Infection, Chapter 5. Johns Hopkins University,
Baltimore, MD. 2001.
2. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human
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Save the
Dates
9th Conference on Retroviruses
and Opportunistic Infections
February 24-28, 2002
Seattle, Washington
Registration: Dec. 10, 2001Jan. 23, 2002
Call: 703.535.6899
Visit: www.retroconference.org
2002 National STD Prevention
Conference
March 4-7, 2002
San Diego, California
Fee: before Feb. 8: $140;
after Feb. 8: $165
Visit: http://www.stdconference.org/
Call: Glenda Vaughn,
404.639.8260
Email: ghv1@cdc.gov
14th National HIV/AIDS Update
Conference (NAUC)
March 19-22, 2002
San Francisco, California
Sponsored by (amfAr) American
Foundation for AIDS Research
Fee: Before Dec. 15: $275;
Dec 15-March 1: $325;
After March 1: $375
(special rates available)
Visit: http://www.amfar.org/cgibin/iowa/nauc/index.html
CME credit available
International Conference on
Emerging Infectious Diseases
(ICEID)
March 24-27, 2002
Atlanta, Georgia
Visit: http://www.cdc.gov/iceid/
Email: cas1@cdc.gov
Clinical Updates in Correctional
Health Care
April 13-16, 2002
Fort Lauderdale, Florida
Fee: before Feb. 15, 2002: $175
Academy members, $250 nonAcademy members; after Feb. 15,
2002: $225 Academy members,
$300 non-Academy members
Visit: www.ncchc.org
Fax: 773.880.2424
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: before Feb. 1, 2002: $850;
Feb.1-May 1, 2002: $950; after
May 1, 2002: $1,050
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
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News Flashes
HIV
Tacoma-Pierce County Proposes Mandatory
Testing of Inmates
Associated Press, 11/19/01
The director of the Tacoma-Pierce County
Health Department in Washington, Dr.
Frederico Cruz-Uribe, has proposed that all jail
inmates arrested on drug- or sex-related
charges be tested for HIV. Dr. Cruz-Uribe has
proposed that these inmates, along with pregnant women and inmates who present with
symptoms of STDs during a doctor’s visit, be
required to undergo HIV testing. Those who
test positive would then be offered counseling
and treatment advice; their sexual and needlesharing partners would be notified. Although
some experts support the proposal, likening the
situation to the eradication of smallpox, other
experts believe these policies undermine civil
rights and that such a policy would not hold up
in court.
New Zidovudine Resistant HIV Found in
Treatment-Naïve Patients
PNAS. 2001; 98:24 (13907-13912).
Researchers from the CDC have detected a
distinct group of HIV-1 viruses in 3.3% of treatment naïve, newly diagnosed HIV-1 positive
patients. These viruses have mutations in the
reverse transcriptase region of the genome that
make these viruses more likely to develop
drug-resistant mutations. These mutations are
different from those known to cause zidovudine
resistance, but indicate a significant potential
for zidovudine (AZT) and possibly stavudine
(d4T) resistance. This is especially troubling
because zidovudine is commonly used in drug
cocktails, experts report. Multi-drug resistant
viruses will have a negative impact on the incidence of HIV and AIDS cases.
Connecticut to Begin HIV Tracking by Name
Hartford Courant, 11/7/01
The Connecticut Department of Public Health
will begin gathering data, including names, of
HIV-positive adults in order to track these individuals. Individuals do have the option to
request anonymity. Health care providers and
clinics will have the responsibility of informing
patients of that option. Although the state commissioner of public health believes that this new
plan serves the needs of the HIV-positive community, other experts claim that the new system
will discourage some individuals from seeking
testing.
HIV Viral Load in Genital Tract and Blood
Not Parallel
Lancet 2001; 358: 9293 (1593-1601).
A study from the Women’s Interagency HIV
Study cohort reports that women who have low
levels of HIV in their blood may still have high
levels of virus in their genital tracts. One-third of

women whose blood viral load was lower than
500 copies/mL still had high levels of HIV in
their genital tracts and experienced genital tract
viral shedding, increasing the rate of transmission through sexual encounters and pregnancies. Some experts believe that genital tract
HIV levels may better estimate the chances of
HIV transmission.

Hepatitis
Oregon Inmates Sue for Hepatitis C
Treatment
Portland Oregonian, 11/2/01
A group of 11 inmates in Oregon have filed suit
against the state Department of Corrections
over the state’s treatment of inmates with
hepatitis C. The group of inmates from the
Salem, Oregon State Penitentiary are claiming
that the policies of the DOC exclude inmates
from HCV treatment and testing. The inmates
are seeking $17.5 million for the treatment of
HCV-positive inmates and mandatory testing of
all new inmates. Corrections officials do not
believe the inmates will win the suit, explaining
that no system in the country has a similar policy.

Tuberculosis
Recurrent TB Infection More Likely in HIVpositive Patients
Lancet, 2001; 358: 9294.
A study of goldmine workers in South Africa has
revealed that HIV-positive individuals were
more likely to experience recurrent tuberculosis
(TB) infection, even after successful completion
of TB therapy. Approximately 27% of the HIVpositive mineworkers experience recurrence of
TB compared to 13.7% of the HIV-negative participants. Recurrence due to relapse was more
common in the HIV-negative participants, while
recurrence due to reinfection was more common among the HIV-positive participants.
However, there was a large number of cases
for which the cause of recurrence was unknown
among the HIV-positive participants. HIV infection was shown to be the most significant risk
factor for reinfection with TB, according to the
study.

CORRECTION:

The titles of the Nelfinavir and Amprenavir
columns in the November 2001 HIV 101
were swapped. The information under the
Nelfinavir column applies to the drug
Amprenavir, and vice versa. The new version of the November 2001 issue with the
correct table is now available online at
http://www.hivcorrections.org. The entire
table will be reprinted in the January 2002
edition of HEPP News.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through June 30, 2002.
The estimated time for completion of this activity is one hour and there is no fee for participation.

CME is Now Available Online at www.hivcorrections.org
1. True or False:
There is now data that support the discontinuation of secondary OI
prophylaxis in those patients who experience sustained ARTinduced immunologic recovery.
(a) True
(b) False
2. In areas endemic to histoplasmosis, which of the following activities should HIV-positive prisoners avoid?
(a) cleaning chicken coops
(b) folding laundry
(c) disturbing the soil beneath bird roosting sites
(d) cleaning or remodeling old buildings
(e) a, c, and d
3. Which of the following are screening tests that should be performed in the work-up of a fever of unknown origin?
(a) CBC
(b) urine culture
(c) blood culture
(d) liver function tests (LFTs)
(e) all of the above
4. If a patient experiences a fever whose origin is unknown, and is
receiving dapsone as part of a treatment regimen, what should be
the physician’s next step?
(a) take a chest x-ray
(b) put the patient on a “drug holiday”
(c) put the patient on empiric antibiotics
(d) treat the patient with penicillin
(e) perform a CT scan of the abdomen and/or the head
5. What is the preferred treatment regimen for treating a mild herpes simplex infection in an HIV-positive patient?
(a) acyclovir 400 mg PO tid for 7-10 days
(b) acyclovir 800 mg PO tid for 7-10 days
(c) no treatment recommended
(d) valacyclovir 1 g PO bid
(e) acyclovir 400 mg PO bid for 7-10 days

6. Which of the following is (are) a preferred treatment regimen(s)
for treating Cytomegalovirus retinitis infection?
(a) Intraocular ganciclovir implant q6 months + oral
valganciclovir 900 mg/day
(b) Valganciclovir 900 mg PO bid x 21 days, then 900 mg/day
(c) Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h x 14 to
21 days
(d) Cidofovir 5 mg/kg 1V q week x2, then 5 mg/kg q 2 weeks +
probenecid, 2 g PO 3 hours before each dose, 1 g PO at 2 and
8 hours post dose
(e) all of the above

HEPP News Evaluation
5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor
1. Please evaluate the following sections with respect to:
educational value

clarity

Main Article

5 4 3 2 1

5 4 3 2 1

HEPPigram

5 4 3 2 1

5 4 3 2 1

HIV 101

5 4 3 2 1

5 4 3 2 1

Save the
Dates

5 4 3 2 1

5 4 3 2 1

2. Do you feel that HEPP News helps you in your work?
Why or why not?

3. What future topics should HEPP News address?

4. How can HEPP News be made more useful to you?

5. Do you have specific comments on this issue?
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